Patent intelligence · US
US 6040340
Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in com…
Patent details — US 6040340
- Jurisdiction
- US
- Status
- expired
- Grant date
- Mar 21, 2000
- Expiration
- Mar 16, 2020
- Claims
- 27
- CPC classes
- A61K, A61K31/198, A61K31/223, A61K31/34
Quick answer
US 6040340 (Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors) is held by The Board of Regents, Univ. of Texas System. Status: expired. Granted Mar 21, 2000. Expires Mar 16, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 27
- CPC classes
- A61K, A61K31/198, A61K31/223, A61K31/34, A61K31/44, A61K31/4402
More from The Board of Regents, Univ. of Texas System
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 6040340?
US 6040340 (Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors) is held by The Board of Regents, Univ. of Texas System. Status: expired. Granted Mar 21, 2000. Expires Mar 16, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6040340?
The Board of Regents, Univ. of Texas System is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 6040340 expire?
Our index shows an expiration date of Mar 16, 2020 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.